Moderna and takeda announce plans to transfer marketing authorization for spikevax(tm) covid-19 vaccine in japan to moderna

Moderna to become marketing authorization holder in japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for spikevaxtm from august 1, 2022 companies concluded memorandum of understanding that takeda will continue to provide distribution support for the moderna covid-19 vaccines for a transitional period cambridge, ma. and osaka, japan / accesswire / may 31, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, and takeda (tse:4502)(nyse:tak) have announced the transfer of the marketing authorization for moderna's covid-19 vaccine spikevaxtm (mrna-1273) from takeda to moderna in japan as of august 1, 2022.
MRNA Ratings Summary
MRNA Quant Ranking